PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Metformin hydrochloride - Diabetes Mellitus
PAD Profile : Metformin hydrochloride - Diabetes Mellitus
Keywords :
Renal Impairment, Kidney Disease, metformin dose titration, metformin intolerance, metformin side effects
Brand Names Include :
Glucophage SR, Bolamyn SR, Diagemet XL, Glucient SR, Metabet SR, Sukkarto SR
Traffic Light Status
Status 1 of 2.
Status :
Green
Important
Preferred
Formulations :
- Modified release tablets
- Tablets
Important Information :
NOTE: 1g oridnary tablets are disproportionately expensive in primary care. 1g modified release tablets are recommended.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Status :
Green (see narrative)
Important
Formulations :
- Oral solution
- Powder
Important Information :
Oral solution should be reserved for patients with enteral feeding tubes or those unable to swallow tablets.
Sachets of powder for oral solution are preferred in patients with swallowing difficulties in primary care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Dapagliflozin
- Exenatide
- Insulin detemir
- Liraglutide
- Pioglitazone hydrochloride
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
- Empagliflozin
- Xultophy
- Insulin Glargine - Toujeo
- Dulaglutide
- Insulin glargine - Abasaglar
- Insulin degludec
- Insulin aspart - NovoRapid
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Gliclazide
- Acarbose
- Insulin Aspart - Trurapi
- Repaglinide
- Glimepiride
- Glipizide
- Glibenclamide
- Tolbutamide
- Albiglutide
- Insulin pump - Type 1 diabetes
- Semaglutide
- Ertugliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Glyxambi (Linagliptin/empagliflozin)
- Sotagliflozin
- Semaglutide (oral)
- Tirzepatide
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Alogliptin/metformin
- Linagliptin/metformin
- Empagliflozin/metformin
- Canagliflozin/metformin
- Dapagliflozin/metformin
- Saxagliptin/dapagliflozin
- Metformin hydrochloride/pioglitazone
- Diazoxide
- Glucose
- Soluble insulin - Hypurin porcine neutral
- Insulin Lispro - Lyumjev
- Insulin Lispro - Humalog
- Insulin Aspart - Fiasp
- Soluble insulin - Humulin R
- Soluble insulin - Humulin S
- Soluble insulin - Actrapid
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Isophane (neutral insulin) - hypurin porcine 30/70
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Isophane Insulin - Humulin I
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
07 February 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Metformin should be considered as the drug of first choice particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.
Appropriate dose titration and patient education will reduce the likelihood of metformin intolerance - see dose titration guide below.
Advice on use of metformin in renal impairment was previously considered by the PCN in June 2015 (Please see policy statement PCN163-2015) for further information
Associated BNF Codes
06. Endocrine System
06.01.02. Antidiabetic drugs